Skip to content

Postoperative pain relief after ultrasound-guided axillary brachial plexus block: A randomized, double-blinded comparison between levobupivacaine and levobupivacaine with dexamethason.

Postoperative pain relief after ultrasound-guided axillary brachial plexus block: A randomized, double-blinded comparison between levobupivacaine and levobupivacaine with dexamethason. - Postoperative pain relief after ultrasound-guided axillary brachial plexus block: A randomized, double-blinded comparison between levobupivacaine and levobupivacaine with dexamethason.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000011406
Enrollment
100
Registered
2013-08-07
Start date
2013-08-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fracture of the distal radius

Interventions

0.5 % levobupivacaine 20 ml with dexamethasone 6.6 mg is administered for ultrasound-guided axillary plexus block. 0.5 % levobupivacaine 20 ml with saline 2 ml is administered for ultrasound-guided ax

Sponsors

Department of Anesthesiology, Fukuseikai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The patient scheduled for osteosynthesis of distal radius and who underwent ultrasound-guided axillary brachial plexus block

Exclusion criteria

Exclusion criteria: Patients who received corticosteroids or opioids, Patients with neuropathy in the affected side, Diabetes, Mental illness, Dementia

Design outcomes

Primary

MeasureTime frame
The time when patients required an initial analgesic postoperatively. The value of VAS at the time of leaving the operating room. The value of VAS at the time the pain appeared. The value of VAS at the time of using analgesics. The value of VAS at the time of the next morning of surgery.

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026